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Background: Until recently, treatments for older patients with AML ineligible to receive
intensive chemotherapies were limited to hypomethylating agents, low-dose cytarabine
(LDAC), or clinical trials. In 2018, the FDA approved combination glasdegib (GLAS) plus
LDAC based on Phase II results demonstrating improved overall survival (OS) versus LDAC
alone in previously untreated AML. However, no randomized clinical trials have directly
compared GLAS + LDAC with other AML treatments.
Objective: Using both indirect treatment comparison (ITC) and simulated treatment comparison
(STC), which adjusts for baseline differences between trials, the comparative effectiveness of
GLAS + LDAC was compared with hypomethylating agent azacitidine (AZA) or decitabine
(DEC).
Methods: A systematic literature review identiﬁed published trials of AZA or DEC versus
LDAC among older AML patients ineligible for high-intensity chemotherapy. In addition to
standard and covariate-adjusted ITC, STC was performed following guidance from the NICE
Decision Support Unit (DSU). Using individual patient data from the Phase II
GLAS + LDAC study, population-speciﬁc OS hazard ratios (HR) for GLAS + LDAC versus
AZA or DEC were compared. Furthermore, covariate-adjusted ITC (Cox multivariate mod-
els) and STC were repeated using GLAS + LDAC versus LDAC data propensity-weighted
for within-trial mean cytogenetic risk. As this initial step was not speciﬁed in the DSU,
results from this second method were compared to the ﬁrst STC following DSU guidance
only.
Results: Standard ITC and STC both demonstrated signiﬁcantly improved OS for
GLAS + LDAC versus either AZA or DEC. Adjusting for key covariates, STC stepwise
exponential models demonstrated GLAS + LDAC superiority to both AZA (HR=0.424; 95%
CI: 0.228, 0.789) and DEC (HR=0.505; 95% CI: 0.269, 0.949). These signiﬁcant results held
using full or step-wise approaches, following DSU guidance only or the weighted STC
approach.
Conclusion: Using ITC and STC, GLAS + LDAC demonstrated superior OS to AZA or DEC in
an adult population with previously untreated AML for whom intensive chemotherapy is not an
option.
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Introduction
Acute myeloid leukemia (AML) is characterized by the
production of high levels of immature myeloid cells in the
bone marrow. Older AML patients face a much lower 5-year
survival rate than their younger counterparts (8% for those
aged 60–65 years vs 38% for those under 45 years) (2) and,
despite increased survival rates since the 1990s for those
younger than 55, survival among elderly patients has not
improved.1 The differences in survival rates have been attrib-
uted to unfavorable prognostic factors associated with older
age, less aggressive therapeutic options,2 and a lack of clin-
ical trial participation, as elderly patients with poor perfor-
mance status or comorbid conditions are often not well
enough to receive intensive chemotherapy.3,4
Although there are limited options for treating older
AML patients ineligible to receive intensive chemotherapy
(NIC), lower intensity chemotherapies such as low-dose
cytarabine (LDAC) or hypomethylating agents such as
azacitidine (AZA) and decitabine (DEC) may be
administered.3 Phase III clinical trial results have tenta-
tively supported the use of AZA or DEC over LDAC in
NIC patient populations, although primary endpoint ana-
lyses failed to ﬁnd signiﬁcant differences in overall survi-
val (OS) between AZA and LDAC 20 mg twice per day
(BID) or DEC and a control arm that included LDAC
(20 mg/m2 daily).5,6 Recently, the FDA approved combi-
nation glasdegib and LDAC 20 mg BID (GLAS + LDAC)
for NIC AML patients.7 Supportive evidence was based on
Phase II trial results (BRIGHT AML 1003) in which
GLAS + LDAC showed a clinically meaningful and sta-
tistically signiﬁcant improvement in OS relative to LDAC
alone.8,9
For treatments that have not been directly compared in
head-to-head clinical trials, such as between GLAS +
LDAC, AZA, and DEC, indirect treatment comparison
(ITC) is a robust method used to estimate relative efﬁcacy
including OS hazard ratios (HR). Standard (Bucher) ITC
accounts for within-trial differences in efﬁcacy between
active treatment and control prior to comparing active
treatment efﬁcacy across trials.10 However, standard ITC
methods in and of themselves do not adjust for between-
trial differences in patient baseline characteristics.
Consequently, the resultant unadjusted relative treatment
effects can generate biased results if there is large variation
in patient populations and trial designs that modify or
affect the treatment effect.11
While standard ITC approaches compare published
aggregate trial data, a recently popularized method, simu-
lated treatment comparison (STC), adjusts for covariates
within the available individual patient data (IPD).11,12
First, different models using the IPD are explored to best
estimate within-trial treatment effects. Second, population
differences relative to comparator trials are accounted for
through covariate adjustment. In this study, IPD were
extracted from the GLAS + LDAC versus LDAC trial
for adult patients with previously untreated AML. Two
different STCs, ﬁrst of GLAS + LDAC versus AZA and
then GLAS + LDAC versus DEC, were performed to
provide population-speciﬁc estimates of OS. As a last
step in STC, a ﬁnal (standard) ITC was performed to
ﬁnalize the comparative effectiveness between trials.
Materials and methods
Overview of ﬁnal study selection and
simulated treatment comparison
The initial ITCs of unadjusted GLAS + LDAC versus
published AZA or DEC results were conducted. ITCs and
STCs were performed following general guidance published
by the Decision Support Unit (DSU) of the National
Institute for Health and Care Excellence.11 Published trials
of DEC or AZA with comparable AML high-risk patient
populations to the GLAS + LDAC study were identiﬁed
through a systematic literature review (SLR). Details of the
SLR are provided in the Appendix, Table S1 and Figure S1.
Final study inclusion in the ITC and STC was limited to
trials with sufﬁcient reporting on patient and trial character-
istics to determine comparable patient eligibility and AML
disease characteristics across studies, and to inform of poten-
tial prognostic factors and effect modiﬁers (Table S2).
While standard ITC does not adjust for population differ-
ences across trials, the results generated with this robust
method were also presented for comparison. Justiﬁcation
for STC, as discussed by the DSU (Figure S2), requires the
presence of within-trial effect modiﬁcation and different dis-
tributions of effect modiﬁers across studies.11 In this context,
effect modiﬁers are deﬁned as covariates that modify the
effect of treatment, so that estimates of treatment efﬁcacy
vary across strata of the effect modiﬁer. Additionally, the
DSU encourages adjustment for additional effect modiﬁers
and prognostic factors (affecting survival outcomes directly)
to produce more precise estimates of relative treatment
effects. These effect modiﬁers and prognostic variables can
Tremblay et al Dovepress
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be identiﬁed in the IPD, relevant disease literature, and by
clinician expertise.
In addition to BRIGHT AML 1003 reporting on
GLAS + LDAC versus LDAC results from the available
IPD, two studies met the ﬁnal selection criteria: Dombret
et al (2015) comparing AZA to LDAC, and Kantarjian et
al (2012) comparing DEC to LDAC.5,6 The baseline char-
acteristics of each study’s participants are summarized in
Table 1. To limit heterogeneity and to make appropriate
population comparisons, subgroups from each of the three
studies were extracted. As Cortes et al (2016) pooled both
AML (n=116) and myelodysplastic syndrome patients
(MDS) (n=16) when reporting baseline characteristics
and outcomes, the available IPD were restricted to AML
patients only.
Even though Kantarjian et al (2012) reported baseline
characteristics for multiple comparator arms, only DEC
(n=242) and LDAC alone (n=215) covariate values were
extracted. However, the published OS HR comparing DEC
to LDAC pooled the 28 patients from the supportive care
arm with the LDAC arm. In the Dombret et al (2015) study,
investigators determined the most appropriate AZA com-
parator between best supportive care (BSC), LDAC or
intensive chemotherapy (IC) prior to randomization.
Patients were then randomly assigned to receive AZA or
the investigator’s predetermined choice of treatment. While
the reported AZA population (n=241) baseline characteris-
tics included patients suitable for BSC, LDAC or IC, the
published OS HR extracted for ITC and STC compared the
subgroup of AZA patients pre-selected for LDAC suitabil-
ity (n=158) against the LDAC arm (n=154). With the
selected studies, a network of randomized controlled trials
(RCTs) was established that applied the LDAC treatment
arm as the common comparator (Figure 1).
Overview of STC approach
Based on the general guidance provided by the DSU for
conducting STC as a starting point, further speciﬁc multi-
stepped criteria were developed using the GLAS + LDAC
STCs as a case study. The criteria were guided by the
publication Tremblay et al (2015), and are summarized in
Figure 2.14 First, exploration of parametric models (includ-
ing proportional and non-proportional hazards models) was
conducted to determine the optimal modelling of efﬁcacy
for GLAS + LDAC versus LDAC. Variable selection to
develop the optimal models explored mutually available
covariates ﬁrst between the GLAS + LDAC IPD and the
AZA trial, and second between the same GLAS + LDAC
IPD and the DEC trial. After including key covariates as
described in criterion 1 (Figure 2), the resultant ﬁt statistics
(criterion 2), graphs of the survival curves (criterion 3) and
survival estimates (criterion 4) for GLAS + LDAC versus
LDAC were compared between models for comparability
and predictive ability using the unadjusted Cox regression
and Kaplan-Meier (KM) estimates as references. These
unadjusted analyses replicated intent-to-treat protocol
estimates.
Once an optimal model was selected from the
GLAS + LDAC trial with IPD, the published mean (aggre-
gate) covariate values from each of the comparator study
populations were substituted into that model. Covariate
adjustment of the optimal models allowed estimation of
efﬁcacy between GLAS + LDAC versus LDAC in each of
the comparator (AZA or DEC) populations. Visual inspec-
tion (criterion 3) and prediction validation (criterion 4)
were repeated for the covariate-adjusted results. New,
adjusted OS HRs estimating GLAS + LDAC versus
LDAC were obtained for each of the comparator popula-
tions AZA and DEC. These OS HRs with simulated AZA
or DEC populations were compared against adjusted Cox
models, which included the same set of covariates. As a
last step in STC, the new, covariate-adjusted HRs for OS
were entered into ITC against the published HRs for AZA
versus LDAC, and DEC versus LDAC. These ﬁnal ITCs
separately estimated indirect OS HRs for GLAS + LDAC
versus AZA and GLAS + LDAC versus DEC. All standard
ITCs utilized the Bucher (1997) method with 95% CIs.10
All analyses were performed using Microsoft Excel
2016 and Stata (version 15.1; StataCorp LLC, College
Station, TX, USA).
Variable selection (criterion 1)
Based on DSU guidance, the decision to retain a variable
for covariate adjustment was based on the variable meet-
ing four criteria: 1) availability in studies being compared,
2) imbalance in distribution across trials, 3) demonstration
of potential effect modiﬁcation, and 4) impact on results
estimating GLAS + LDAC versus LDAC OS HR. STC
full covariate adjustments created more similar popula-
tions between trials. Additionally, to increase model pre-
cision as per DSU guidance, exploration was repeated with
reduced models, including variables that met at least one
“stepwise” criterion: the presence of a statistically signiﬁ-
cant covariate from both the full and reduced models,
identiﬁcation as an effect modiﬁer in at least one of the
Dovepress Tremblay et al
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trials, or being retained as a stratiﬁcation factor (eg, cyto-
genetic risk factor) from the original three trials. Of note,
the set of stepwise variables could be different for
GLAS + LDAC versus AZA and GLAS + LDAC versus
DEC comparisons, based on each trial’s design and report-
ing of results.
Model exploration and comparison of
functional forms (criterion 2)
In order to ﬁrst determine the optimal regression model to
estimate treatment effects of GLAS + LDAC versus
LDAC, both full models and reduced (stepwise) models
were explored, following recommendations by Tremblay
Drug B:
glasdegib + low - dose
cytarabine
(GLAS+LDAC)
Drug C:
azacitidine (AZA) or
decitabine (DEC)
Drug A:
low-dose cytarabine
(LDAC)
Figure 1 Comparison network.
Notes: In the above comparison network, LDAC alone is the common comparator between trials. In the GLAS + LDAC versus LDAC (Cortes 2016) trial and AZA versus
LDAC (Dombret 2015) trial, LDAC was administered as 20 mg twice per day . In the DEC vs LDAC (Kantarjian 2012) trial, LDAC was administered as 20 mg/m2 once daily .
Either dose schedule is considered to have comparable drug concentration over time (area under the curve) which includes any associated cytotoxic effects.13
Abbreviation: AML, acute myeloid leukemia.
Figure 2 Multi-stepped criteria to conduct and evaluate simulated treatment comparisons.
Abbreviations: AFT, accelerated failure time; AIC, Akaike’s information criterion; BIC, Bayesian information criterion.
Dovepress Tremblay et al
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et al (2015).14 Exploration used Cox regression estimation
to compare with parametric modelling of proportional
hazards (PHs; exponential, Weibull, Gompertz) and non-
proportional, accelerated failure time (AFT) models
(loglogistic, lognormal, gamma). Appropriate use of Cox
regression modelling was tested by visual assessment of
the log-cumulative hazard plots, as well as the Schoenfeld
global test of proportionality.15,16,17 Unadjusted Cox
regression models only included the treatment covariate.
Model ﬁt statistics, including Akaike’s information criter-
ion (AIC), Bayesian information criterion (BIC), the log-
likelihood, and chi-square, were compared between all
models, to inform of optimal stepwise and full adjust-
ments. To obtain HRs at the median OS (duration) for
the AFT models, the hazard rates within each trial arm
were constructed from the difference in the natural log of
the survival between each month. These hazard rates were
then summed and divided between trial arms to obtain the
HR for each month. Exploration of the six models (PH:
exponential, Weibull, Gompertz; AFT: loglogistic, lognor-
mal, gamma) was performed for each of the two STCs.
Visual inspection and prediction validation
(criteria 3 and 4)
In order to assess the comparability of each model’s predic-
tive ability, continuous survival outcomes were estimated
with each of the six models, which were compared with
original KM estimates for GLAS + LDAC versus LDAC.
Post-regression predictions in Stata were performed to esti-
mate average survival (proportion alive), median OS
(months) and extended mean OS (months) for both
GLAS + LDAC and LDAC alone. Additionally, OS HRs
derived from Cox unadjusted and fully adjusted multivariate
models were compared against OS HRs estimated from the
three PH and three AFT models. Survival curves graphed
separately for GLAS + LDAC and LDAC arms were visually
compared with the original trial’s (unadjusted) KM curves.
To further evaluate visual evidence for selecting the optimal
model, each model’s HR, including the proportional models
producing static HRs, was plotted over 20months (maximum
duration of survival in the LDAC treatment group). While an
exact match of adjusted and unadjusted estimates was not
expected, reasonably similar results were desired.
Covariate adjustment
Once an optimal model was selected (eg, from the mutual
set of covariates between the GLAS + LDAC and AZA
trials), the mean covariate values of the AZA treatment arm
were entered into the optimal model to simulate the
GLAS + LDAC versus LDAC comparison being performed
among the AZA patients. New predictions including cov-
ariate-adjusted survival curves (criterion 3), survival times
(criterion 4) and OS HR (criterion 4) were generated and
compared with the original IPD population estimates. The
same covariate adjustment was performed substituting the
DEC population to simulate the GLAS + LDAC versus
LDAC comparison among DEC patients.
Indirect treatment comparisons
ITCs were separately conducted for GLAS + LDAC ver-
sus AZA and GLAS + LDAC versus DEC. First, standard
(Bucher) ITC compared unadjusted OS HRs from original
publications. The second ITC approach applied Cox multi-
variate regression of GLAS + LDAC versus LDAC IPD
against AZA or DEC published OS HRs. Finally, as the
last step in STC, the STC-derived estimates of
GLAS + LDAC versus LDAC efﬁcacy entered ﬁnal ITC
against AZA or DEC. Optimal models from the STC
model exploration were selected into the ﬁnal ITC,
which included full and stepwise adjustments.
Results
Glasdegib + LDAC versus azacitidine:
estimating indirect overall survival hazard
ratios
All full covariate models applied in GLAS + LDAC ver-
sus AZA comparisons included all of the baseline char-
acteristics mutually available between studies: age, sex,
AML type, proportion of bone marrow blasts <50%,
Eastern Cooperative Oncology performance status
(ECOG PS), cytogenetic risk, and hemoglobin level.
Decisions for variable selection for the stepwise model
are summarized in Table 2, based on the criteria described
above. All stepwise models included age, sex, and poor
cytogenetic risk.
Comparison of functional forms and model ﬁt
statistics
Visual assessment of the hazard plots and the Schoenfeld test
of proportionality for the full (p=0.27) and stepwise (p=0.97)
Cox models indicated no statistically signiﬁcant deviation
from the PH assumption. Fit statistics AIC and BIC were
similar between full (615/637) and stepwise (617/628) Cox
models, with the next best ﬁt statistics resulting from the
Tremblay et al Dovepress
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stepwise exponential model (343/359). For all full and step-
wise model parametrizations, the Chi-square tests for the log
likelihood demonstrated signiﬁcance for at least one of the
included variables in the OS HR regression, and the expo-
nential and Weibull stepwise models had the smallest asso-
ciated p-values (p=0.0002 and p=0.0001, respectively).
Visual inspection
The graph of HRs over time demonstrated that all parametric
estimates were comparable to the Cox model (not shown),
with strong areas of overlap between all models (including
AFT) occurring around their similar median OS durations in
the GLAS + LDAC arm (8–9 months). The graphs of the
survival curves separated by treatment group (GLAS+LDAC
or LDAC alone) were generated twice using slightly different
approaches. First, STC models (parametric) were developed
by applying the IPD of the subgroup of AML patients from
GLAS + LDAC versus LDAC and following DSU guidance
(Figure 3A and B). Second, to improve visual ﬁt of the para-
metric survival curves with respect to the KM,
GLAS + LDAC versus LDAC IPD were propensity-
weighted for trial-level cytogenetic risk. Cytogenetic risk
was the trial stratiﬁcation factor during randomization of the
original AML+MDS population to each treatment arm. After
weighting, all STC steps were repeated to generate a second
set of results (Figure 4A and B). From the ﬁrst set of results
applying GLAS + LDAC versus LDAC IPD, the exponential
curves had the closest ﬁt to the KM curves compared with
other distributions, but potentially did not convey an ideal
visual ﬁt. From the second set of results applying weighted
trial data, all parametric extrapolations improved their visual
ﬁt to the KM. Among stepwise models, the Weibull distribu-
tion had the closest visual ﬁt to the KM. Of the full covariate
models, the exponential distribution demonstrated the closest
visual ﬁt to the KM. All visual evidence for the full and
stepwise adjusted survival curves conveyed a signiﬁcant treat-
ment effect for GLAS + LDAC compared with LDAC alone,
with stepwise models showing somewhat greater magnitude
of treatment effect compared with full models.
Prediction validation
In estimating OS with GLAS + LDAC versus LDAC IPD,
among the PH models, exponential and Gompertz distribu-
tions produced the most similar OS HR, OSmedian, and OS
Table 2 Variable selection: GLAS + LDAC vs AZA
Full Model Results Statistical
Evidence
Justiﬁcation for Inclusion in Stepwise Models
Included Baseline
Characteristics
GLAS + LDAC
(IPD)
AZA
(Dombret
2015)
GLAS + LDAC
versus LDAC IPD
Cox p-value
Mean age at baseline 75.9 75.0 0.54 Included due to signiﬁcant treatment effect for subgroup age
<75 years but not age ≥75 years in Dombret 2015
Sex, male 70.7% 58.4% 0.41 Included due to signiﬁcant treatment effect for females but
not males in Dombret 2015, prognostic in the literature, large
imbalance between trials
AML type, de novo 48.3% 82.0% 0.52 Excluded for lack of signiﬁcance in GLAS + LDAC versus LDAC
IPD regression and no subgroup analysis in Dombret 2015
Bone marrow blasts
>50%
47.9% 75.4% 0.52 Excluded for lack of signiﬁcance in GLAS + LDAC versus LDAC
IPD regression and lack of signiﬁcance in Dombret 2015
ECOG PS 0 or 1
versus 2
49.1% 77.4% 0.91 Excluded for lack of signiﬁcance in GLAS + LDAC versus LDAC
IPD regression and no subgroup analysis in Dombret 2015
Cytogenetic risk:
poor versus good/
intermediate
39.6% 34.8% - Included due to being a stratiﬁcation factor in both trial
protocols
Median baseline
hemoglobin level (g/dL)
9.2 9.4 0.59 Excluded for lack of signiﬁcance in GLAS + LDAC versus LDAC
IPD regression and no subgroup analysis in Dombret 2015
Abbreviations: AML, acute myeloid leukemia; AZA, azacitidine; DSU, Decision Support Unit; ECOG PS, Eastern Cooperative Oncology Group performance status; GLAS,
glasdegib; IPD, individual patient-level data; LDAC, low-dose cytarabine.
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estimates to Cox regression estimates, for both stepwise and
full model comparisons. The exponential model, over
Gompertz, had slightly better model ﬁt statistics; therefore,
exponential was considered the optimal PH model. When
applying propensity- weighted trial data of GLAS + LDAC
versus LDAC, exponential and Weibull models generated
highly similar survival predictions and model ﬁt statistics.
For optimal model selection, exponential was chosen again
for full covariate modelling. Among stepwise models,
Weibull was slightly favored over exponential due to visual
ﬁt criteria. Among the AFT models using either the
unweighted or propensity-weighted trial data, gamma had
the most reasonable survival estimates, although AIC and
BIC were somewhat higher due to a more complex model
than PH. All model results (PH and AFT) demonstrated
GLAS + LDAC superiority over LDAC.
Covariate adjustment
Results from applying the mean covariate values from
the AZA population to the GLAS + LDAC versus
LDAC comparison continued to demonstrate signiﬁcant
treatment effects among the simulated AZA population.
As the chosen optimal model from following DSU gui-
dance (Table 3), the stepwise exponential approach esti-
mated slightly improved GLAS + LDAC efﬁcacy versus
LDAC (HR=0.382; 95% CI: 0.217, 0.673) compared
with estimates from the Cox stepwise covariate model
(HR=0.395; 95% CI: 0.219, 0.712). Likewise, in the
weighted trial data for GLAS + LDAC versus LDAC
(Table 4), the stepwise Weibull model estimated a
slightly lower OS HR (HR=0.371; 95% CI: 0.203,
0.677) compared with the Cox stepwise model
(HR=0.395; 95% CI: 223, 0.702).
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Figure 3 Overlay of Kaplan-Meier with exponential parametrization adjusting trial IPD (A) AZA and (B) DEC populations.
Notes: In Figure 3A (AZA) and 3B (DEC), the gray (KM) and both blue (exponential) curves represent OS in the LDAC alone treatment arm. The orange and green lines
estimate survival time in the GLAS + LDAC arm. The solid curves apply the average covariate values from the IPD population, while the dashed curves model the mean
covariates from the comparator trials (AZA or DEC).
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; K-M, Kaplan-Meier; LDAC, low-dose cytarabine; IPD, individual patient data; OS, overall survival.
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An overlay (see Figures 3A and 4A) of the original
KM and stepwise exponential survival curves applying
either the GLAS + LDAC versus LDAC IPD population
(solid lines) or simulated AZA population (dashed lines)
demonstrates similarity between the populations when
graphing GLAS + LDAC versus LDAC.
Indirect treatment comparisons
Table 3 summarizes results from the standard (initial) ITC
(row 1) and covariate-adjusted ITC (row 2). The DSU-guided
STC-generated HRs entered ﬁnal ITC (rows 3 and 4). Table 4
presents the results from the weighted STC approach (rows 3
and 4). The ﬁrst row is repeated in Tables 3 and 4, as standard
ITC did not apply weighting or covariate adjustment.
The full Cox model (adjusted with mutually available
covariates between GLAS + LDAC and AZA studies) is also
included in a separate ITC against the AZA published HR
(row 2).
The third and fourth rows present the ﬁnal ITC results (the
STC models) derived from the stepwise and full exponential
STC adjustments, respectively. All models, following DSU
guidance (Table 3) or the weighted STC approach (Table 4),
found that GLAS + LDAC was signiﬁcantly associated with
Figure 4 Overlay of Kaplan-Meier with Weibull parametrization for the weighted STC approach (A) AZA and (B) DEC populations.
Notes: In Figure 4A (AZA) and 4B (DEC), the gray (KM) and both blue (Weibull) curves represent OS in the LDAC alone treatment arm. The orange and green lines
estimate survival in the GLAS + LDAC arm. The solid curves apply the average covariate values from the IPD population, while the dashed curves model the mean covariates
from the comparator trials (AZA or DEC).
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; K-M, Kaplan-Meier; LDAC, low-dose cytarabine; IPD, individual patient data; OS, overall survival; STC,
simulated treatment comparison.
Dovepress Tremblay et al
ClinicoEconomics and Outcomes Research 2019:11 submit your manuscript | www.dovepress.com
DovePress
559
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
80
.2
29
.2
44
 o
n 
25
-S
ep
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
improved OS when compared with AZA (two rightmost col-
umns). Compared with the result using only the standard ITC
(HR=0.514; 95% CI: 0.310, 0.852), adjusting for population
covariates resulted in slightly stronger treatment effects of
GLAS + LDAC in comparison to AZA.
A forest plot of the GLAS + LDAC versus AZA DSU-
guided comparisons (Fig 5A, AZA comparison), based on
average-adjusted standard errors, illustrates the slight narrow-
ing of the CIs between the stepwise and full exponentially
derived results. In Figure 6A, (AZA comparison) weighted
GLAS + LDAC versus published AZA also demonstrated
statistically signiﬁcant favor of GLAS + LDAC over AZA.
Glasdegib + LDAC versus decitabine:
estimating indirect overall survival hazard
ratios
The second STC compared GLAS + LDAC to DEC
(Kantarjian, 2012).6 Of the mutually available variables
between the GLAS + LDAC and DEC studies that were
all used in the full models, those selected for the stepwise
models included age, AML type, proportion bone marrow
blasts >50%, ECOG PS, and cytogenetic risk, as summar-
ized in Table 5.
Comparison of functional forms and model ﬁt
statistics
The second STC also involved visual assessment of the
hazard plots and the Schoenfeld test for the Cox stepwise
model. As in the ﬁrst STC, no signiﬁcant deviations from
the PH assumption was found (p=0.65). The stepwise
approach for both Cox and parametric models demon-
strated improved AIC/BIC values compared with the full
models, resulting in a more robust model measuring
greater signiﬁcance in treatment effects. Across all para-
metrizations (PH and AFT models), the Chi-square tests
for the log likelihood demonstrated signiﬁcance for at least
one of the included variables, and the exponential and
Weibull models had the smallest associated p-values
(p=0.0008 for both). Again, while the exponential, step-
wise parametrization demonstrated numerically superior
AIC/BIC ﬁt statistics (345/367), all of the tested stepwise
model forms demonstrated comparable ﬁt.
Visual inspection
Following DSU guidance with GLAS + LDAC versus
LDAC IPD, lognormal and loglogistic appeared to have the
strongest visual ﬁts early in the analysis time. However, over
all trial time, the exponential model showed strong visual ﬁt.
Table 3 ITC Cox and STC exponential model results: AZA comparison, DSU guidance
Treatments Compared: model GLAS + LDAC vs
LDAC
AZA vs LDAC
(published)
GLAS + LDAC vs
AZA
HR 95% CI HR 95% CI HR 95% CI
GLAS + LDAC vs AZA: Cox unadjusted (standard ITC)* 0.463 0.299, 0.717 0.900 0.700, 1.160 0.514 0.310, 0.852
GLAS + LDAC vs AZA: Cox full (multivariate ITC)** 0.418 0.224, 0.779 0.900 0.700, 1.160 0.464 0.237, 0.910
GLAS + LDAC vs AZA: stepwise exponential (STC) 0.382 0.217, 0.673 0.900 0.700, 1.160 0.424 0.228, 0.789
GLAS + LDAC vs AZA: full exponential (STC) 0.401 0.219, 0.736 0.900 0.700, 1.160 0.446 0.231, 0.860
Notes: *This row is equivalent to performing standard (unadjusted) ITC comparing GLAS + LDAC to AZA. **This row performs a covariate-adjusted ITC. Bolded values in
GLAS + LDAC vs AZA column are meant to highlight results of ITC and STC analysis.
Abbrevations: AZA, azacitidine; GLAS, glasdegib; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment comparison; DSU, Decision
Support Unit; HR, hazard ratio.
Table 4 ITC Cox and STC exponential model results: AZA comparison, weighted STC approach
Treatments Compared: Model GLAS + LDAC vs
LDAC
AZA vs LDAC
(published)
GLAS + LDAC vs
AZA
HR 95% CI HR 95% CI HR 95% CI
GLAS + LDAC vs AZA: Cox unadjusted (standard ITC)* 0.463 0.299, 0.717 0.900 0.700, 1.160 0.514 0.310, 0.852
GLAS + LDAC vs AZA: Cox full (multivariate ITC)** 0.425 0.227, 0.797 0.900 0.700, 1.160 0.473 0.240, 0.930
GLAS + LDAC vs AZA: stepwise Weibull (STC) 0.371 0.203, 0.677 0.900 0.700, 1.160 0.412 0.214, 0.791
GLAS + LDAC vs AZA: full exponential (STC) 0.396 0.216, 0.725 0.900 0.700, 1.160 0.440 0.228, 0.848
Notes: *This row is equivalent to performing standard (unadjusted) ITC comparing GLAS + LDAC to AZA. **This row performs a covariate-adjusted ITC with propensity-
weighted GLAS + LDAC vs LDAC data. Bolded values in GLAS + LDAC vs AZA column are meant to highlight results of ITC and STC analysis.
Abbreviations: AZA, azacitidine; GLAS, glasdegib; HR, hazard ratio; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment
comparison.
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After applying weighted trial data, the exponential model
continued to demonstrate close visual comparison to the
KM. However, among the stepwise models, the Weibull
distribution demonstrated a somewhat stronger visual ﬁt.
With either approach, the graphs of the HRs over 20 months
(maximum survival in the LDAC alone arm) all had compar-
able estimates of GLAS + LDAC superiority over LDAC,
with strong overlap between parametrizations and the Cox
regression estimate.
Prediction validation
Relative to the unadjusted Cox OS HR and KM survival
outcomes, exponential and Gompertz stepwise models
adjusting original trial IPD (following DSU guidance)
had the closest HR estimates to those of the Cox regres-
sion model. With full models adjusting original trial IPD
or weighted data for GLAS + LDAC versus LDAC, expo-
nential (PH) and gamma (AFT) models provided the most
comparable values for average survival rates and median
and mean OS. With weighted trial data, exponential and
Weibull stepwise models generated similar survival pre-
dictions. All models applying either original IPD or
weighted trial data demonstrated signiﬁcantly higher sur-
vival with GLAS + LDAC over LDAC alone.
After applying the three criteria for determining the
optimal model (statistical ﬁt, visual inspection, prediction
estimation), it was determined that the exponential stepwise
parametrization provided the optimal ﬁt for estimating
GLAS + LDAC versus LDAC efﬁcacy in the DEC popula-
tion when using the GLAS + LDAC versus LDAC IPD.
With propensity-weighted trial data for GLAS + LDAC
versus LDAC, the Weibull distribution among the stepwise
models was considered optimal.
Covariate adjustment
Following DSU guidance, after covariate adjustment to
the GLAS + LDAC versus LDAC IPD to simulate the
DEC population, GLAS + LDAC continued to demon-
strate signiﬁcantly improved survival gains relative to
LDAC (HR=0.414; 95% CI: 0.227, 0.757) for the
Figure 5 Forest plots of exponential and Cox model estimates for (A) GLAS + LDAC versus AZA and (B) GLAS + LDAC versus DEC, DSU guidance.
Notes: The forest plots (95% conﬁdence intervals) demonstrate GLAS + LDAC superiority vs (A) AZA and (B) DEC, and provide a simple visualization of the comparable
HR results among each set of models. The x-axis is presented on the log scale.
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment
comparison.
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stepwise exponential model (Table 6, ﬁrst two columns).
Applying weighted GLAS + LDAC versus LDAC trial
data in the DEC covariate adjustment, the stepwise
Weibull model (Table 7) generated similar results
(HR=0.397; 95% CI: 0.204, 0.772).
Indirect treatment comparisons
Results in Table 6 summarize the standard ITC (row 1),
covariate-adjusted ITC (row 2), and STC (rows 3 and 4)
which compared HRs from DSU-guided STC against the
published OS HR from Kantarjian et al 2012. Results
derived from the stepwise and full exponential models
are shown in rows three and four. Results in Table 7,
presenting ﬁnal indirect comparisons from the weighted
STC approach (rows 3 and 4), demonstrate highly consis-
tent estimates from Table 6.
All ITC and STC approaches found GLAS + LDAC to
have signiﬁcantly superior OS relative to DEC. Compared
with the result only using standard ITC (HR=0.565; 95%
CI: 0.351, 0.909), overall trends found that adjustment for
population covariates resulted in slightly stronger
treatment effects of GLAS + LDAC versus DEC. The
forest plots in Figures 5 and 6 (DEC comparison) provide
a visual comparison of Tables 6 and 7, respectively.
Discussion
In this study, standard ITC and STC methodology devel-
oped from the DSU guidance were applied as a case study
to estimate the OS comparative effectiveness of
GLAS + LDAC versus AZA or DEC. The OS HR was
selected as an estimator of a robust outcome, given that
survival is a key patient relevant outcome, and was the
primary endpoint in the included trials. Because naïve
comparisons across published trial results do not adjust
for within-study differences in treatment survival gains,
such comparisons are inappropriate and subject to multiple
biases. Standard ITC is a robust methodology adjusting for
trial differences in survival gains, and STC adjusts for
biases due to patient population differences across trials.
Our STC modelling approach explored full and step-
wise parametric models, as well as comparisons to Cox
regression and unadjusted KM estimates. Additionally,
Figure 6 Forest plots of exponential and Cox model estimates for (A) GLAS + LDAC versus AZA and (B) GLAS + LDAC versus DEC, weighted STC approach.
Notes: The forest plots (95% conﬁdence intervals) demonstrate GLAS + LDAC superiority vs (A) AZA and (B) DEC, and provide a simple visualization of the comparable
HR results among each set of models. The x-axis is presented on the log scale.
Abbreviations: AZA, azacitidine; DEC, decitabine; GLAS, glasdegib; HR, hazard ratio; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment
comparison.
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STC modelling approaches were repeated for propen-
sity-weighted, within-trial data. Independent of which
models and GLAS + LDAC versus LDAC data were
used to derive ﬁnal HRs, standard ITC and STC results
consistently demonstrated GLAS + LDAC numeric and
statistical superiority over AZA and over DEC. Thus, in
the absence of direct, head-to-head trials, results from
robust indirect comparisons can be more appropriate
than naïve comparisons to support clinical decision-
making.
The primary limitation of this STC analysis is a general
lack of precedence in the published literature and the lack
of speciﬁc guidance from the DSU for estimating hazard
ratios and selecting optimal models such as through step-
wise processes. Furthermore, while the DSU advises
adjusting for population differences when substantial
imbalances exist between trials11, some population differ-
ences may remain unadjusted if these data were not avail-
able in the published comparator trials. Similarly,
summary statistics for some of the covariates in the
Table 5 Inclusion of covariates, GLAS + LDAC vs DEC
Full Model Results Statistical
Evidence
Justiﬁcation for Inclusion in Stepwise Models
Included Baseline
Characteristics
GLAS + LDAC
(IPD)
DEC
(Kantarjian
2012)
GLAS IPD
Cox p-
value
Mean age at baseline 75.9 73.0 0.54 Included due to signiﬁcant treatment effect for only subgroup age ≥
75 years in Kantarjian 2012, potentially prognostic as advised by
clinical expertise
Sex, male 70.7% 58.% 0.41 Excluded for lack of subgroup analysis in Kantarjian 2012
AML type, de novo 48.3% 64.6% 0.52 Signiﬁcant treatment effect for de novo but not secondary AML in
Kantarjian 2012, large imbalance between trials
Bone marrow blasts
>50%
47.9% 42.7% 0.52 Included due to signiﬁcant treatment effect for subgroup >30% in
Kantarjian 2012, large imbalance between trials
ECOG PS 0 or 1
versus 2
49.1% 76.2% 0.91 Included due to signiﬁcant treatment effect for subgroup ECOG =2
in Kantarjian 2012, large imbalance between trials
Cytogenetic risk:
poor versus good/
intermediate
39.6% 36.3% - Included due to being a stratiﬁcation factor in both trial protocols
Median hemoglobin at
baseline
9.2 9.3 0.59 Excluded for lack of signiﬁcance in GLAS + LDAC versus LDAC IPD
regression and no subgroup analysis in Kantarjian 2012
Abbreviations: AML, acute myeloid leukemia; DEC, decitabine; DSU, Decision Support Unit; ECOG PS, Eastern Cooperative Oncology Group performance status; GLAS,
glasdegib; LDAC, low-dose cytarabine.
Table 6 ITC Cox and STC exponential model results: DEC comparison, DSU guidance
Treatments Compared: Model GLAS + LDAC vs
LDAC
DEC vs LDAC
(published)
GLAS + LDAC vs
DEC
HR 95% CI HR 95% CI HR 95% CI
GLAS + LDAC vs DEC: Cox unadjusted (standard ITC)* 0.463 0.299, 0.717 0.820 0.680, 0.990 0.565 0.351, 0.909
GLAS + LDAC vs DEC: Cox full (multivariate ITC)** 0.418 0.224, 0.779 0.820 0.680, 0.990 0.510 0.266, 0.977
GLAS + LDAC vs DEC: stepwise exponential (STC) 0.414 0.227, 0.757 0.820 0.680, 0.990 0.505 0.269, 0.949
GLAS + LDAC vs DEC: STC full exponential (STC) 0.401 0.219, 0.736 0.820 0.680, 0.990 0.490 0.259, 0.924
Notes: *This row is equivalent to performing standard (unadjusted) ITC comparing GLAS + LDAC to DEC. **This row performs a covariate-adjusted ITC. Bolded values in
GLAS + LDAC vs AZA column are meant to highlight results of ITC and STC analysis.
Abbreviations: DEC, decitabine; DSU, Decision Support Unit; HR, hazard ratio; GLAS, glasdegib; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC,
simulated treatment comparison.
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Kantarjian and Dombret trials were published as medians,
and in those instances, a weighted mean between the
comparator trial arms (divided by total patients) was
estimated.
In ITC, and therefore in both the standard ITC and the
last calculation of STC, the 95% CIs around the ﬁnal OS
HRs widen as they are estimated by summing the variance
of the treatment effect estimate from both trials. This can
contribute to less precise estimates compared with the
results of the published, intent-to-treat analyses. Another
population-adjustment ITC method, matching-adjusted
indirect treatment comparison (MAIC), draws inferences
on a subgroup with matching baseline characteristics
across trials.18 However, MAIC can signiﬁcantly reduce
effective sample size, increase uncertainty around point
estimates, and limit population-level interpretation of the
results.11 In the original GLAS + LDAC versus LDAC
AML patient data set, there was a relatively small sample
size (n=116). Thus, a strength of STC is that the full
patient dataset is retained, potentially improving the
robustness of the estimates and enabling greater general-
izability to broader patient populations.
As a last, conceptual step of STC, inference of the ﬁnal
results to a broader, target population, such as patients a
clinician would treat, is supported by its demographic and
clinical protocol similarities to the comparator population
(here AZA or DEC). The results of this study can be
generalized to older patients with previously untreated
AML for whom intensive chemotherapy is not an option.
We present a robust methodologically comprehensive
comparison of population-speciﬁc OS HR results that con-
sistently favored GLAS + LDAC over either AZA or
DEC. While STC may serve as an important comparison
methodology to inform payers’ decision-making and sup-
port clinical inferences by accounting for differences in the
patient populations of published trials, evidence from
robust RCT methodology should be prioritized over
naïve comparisons.
Conclusion
In summary, STC methodology explored several mod-
elling approaches to best estimate GLAS + LDAC ver-
sus LDAC outcomes. The stepwise, exponential and
Weibull STC models adjusting for key covariates
resulted in the optimal model ﬁt and the lowest HRs,
which demonstrated GLAS + LDAC superiority to
AZA and to DEC. Regardless of the modelling techni-
que used, both ITC and STC consistently demonstrated
signiﬁcantly improved OS for GLAS + LDAC relative
to AZA or DEC.
Abbreviations
AFT, accelerated failure time; AIC, Akaike’s information
criterion; AML, acute myeloid leukemia; AZA, azaciti-
dine; BIC, Bayesian information criterion; BID, bis in
die, twice per day; BSC, best supportive care; CI, conﬁ-
dence interval; DEC, decitabine; DSU, Decision Support
Unit; ECOG, Eastern Cooperative Oncology Group; FDA,
US Food and Drug administration; GLAS, glasdegib; HR,
hazard ratio; IC, intensive chemotherapy; IPD, individual
patient data; ITC, indirect treatment comparison; KM,
Kaplan-Meier; LDAC, low-dose cytarabine; MAIC,
matching-adjusted indirect treatment comparison; MDS,
myelodysplastic syndrome; NIC, not eligible for intensive
chemotherapy; NICE, National Institute for Health and
Care Excellence; OS, overall survival; PH, proportional
hazards; PS, performance status; RCT, randomized con-
trolled trial; SLR, systematic literature review; STC, simu-
lated treatment comparison.
Table 7 ITC Cox and STC exponential model results: DEC comparison, weighted STC approach
Treatments Compared: Model GLAS + LDAC vs
LDAC
DEC vs LDAC
(published)
GLAS + LDAC vs
DEC
HR 95% CI HR 95% CI HR 95% CI
GLAS + LDAC vs DEC: Cox unadjusted (standard ITC)* 0.463 0.299, 0.717 0.820 0.680, 0.990 0.565 0.351, 0.909
GLAS + LDAC vs DEC: Cox full (multivariate ITC)** 0.422 0.225, 0.792 0.820 0.680, 0.990 0.515 0.267, 0.992
GLAS + LDAC vs DEC: stepwise Weibull (STC) 0.397 0.204, 0.772 0.820 0.680, 0.990 0.484 0.242, 0.967
GLAS + LDAC vs DEC: STC full exponential (STC) 0.395 0.215, 0.725 0.820 0.680, 0.990 0.482 0.255, 0.909
Notes: *This row is equivalent to performing standard (unadjusted) ITC comparing GLAS + LDAC to DEC. **This row performs a covariate-adjusted ITC with propensity-
weighted GLAS + LDAC vs LDAC data. Bolded values in GLAS + LDAC vs AZA column are meant to highlight results of ITC and STC analysis.
Abbreviations: DEC, decitabine; GLAS, glasdegib; HR, hazard ratio; ITC, indirect treatment comparison; LDAC, low-dose cytarabine; STC, simulated treatment
comparison.
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